Lexeo Therapeutics raised $100m to fund its gene research projects focused on cardiovascular and neurological diseases after reducing the price of its IPO. The New York-based firm’s focus ranges from rare diseases to common conditions with a genetically defined subset. Lexeo’s most advanced projects involve Friedreich’s ataxia, a rare neuromuscular disorder, and Alzheimer’s disease. The funding will also support two clinical-stage programs and others in its development pipeline.
AusCERT launches new Tabletop Exercise Service for cyber incident readiness – CRN Australia
AusCERT has introduced a Tabletop Exercise Service to help organizations prepare for cyber incidents. The service helps identify gaps in incident response plans and improve
